News Releases

These are news releases that are related to our company, pipeline and investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Mar 30, 2016

Summary Toggle aTyr Pharma Appoints Sanjay Shukla, MD, MS, as Chief Medical Officer

SAN DIEGO , March 30, 2016 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced that Sanjay Shukla , MD, MS, has joined the company as Chief
Mar 30, 2016

Summary Toggle aTyr Pharma Announces Encouraging Phase 1b/2 Results for Resolaris™ in its First Rare Myopathy Trial

First patient trial of a Physiocrine-based investigational new drug Preliminary analysis shows potential activity signals in three months of treatment Safety, tolerability, immunogenicity & PK profile supports Resolaris program advancement in FSHD and potentially other rare diseases SAN
Jan 11, 2016

Summary Toggle aTyr Provides Corporate Update And Outlook For 2016

Data for Phase 1b/2 Clinical Trial of Resolaris in Adult FSHD Patients Expected at Approximately the End of First Quarter 2016 SAN DIEGO , Jan. 11, 2016 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE) a biotherapeutics company engaged in the discovery and development of
Jan 7, 2016

Summary Toggle aTyr Pharma to Present at 34th Annual J.P. Morgan Healthcare Conference

SAN DIEGO , Jan. 7, 2016 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced the Company's participation at the 34th Annual J.P.
Jan 6, 2016

Summary Toggle aTyr Pharma Appoints Sanuj Ravindran, M.D., as Chief Business Officer

SAN DIEGO , Jan. 6, 2016 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced that Sanuj Ravindran , M.D., has joined the company as Chief Business
Dec 16, 2015

Summary Toggle aTyr Pharma Added to NASDAQ Biotechnology Index

SAN DIEGO , Dec. 16, 2015 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE) a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced that the Company has been selected for addition to the NASDAQ
Nov 11, 2015

Summary Toggle aTyr Pharma Selects Second IND Candidate, The First Engineered Physiocrine for GMP Process Development and for Potential Treatment of Severe Lung Diseases

SAN DIEGO , Nov. 11, 2015 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced that it has selected an Investigational New Drug (IND) Candidate
Nov 10, 2015

Summary Toggle aTyr Pharma to Host Breakout Session at the 6th Annual World Orphan Drug Congress

SAN DIEGO , Nov. 10, 2015 / PRNewswire / -- aTyr Pharma (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, today announced the Company's participation at the 6 th Annual World Orphan Drug Congress in Geneva,
Nov 10, 2015

Summary Toggle aTyr Pharma Announces Third Quarter 2015 Operating Results

Company Continues Expansion of Resolaris™ Clinical Program and Strengthens Leadership Team with Executive Promotions and New Manufacturing Appointment SAN DIEGO , Nov. 10, 2015 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and
Nov 9, 2015

Summary Toggle aTyr Pharma Initiates Phase 1b/2 Clinical Trial in Patients with Early Onset FSHD

SAN DIEGO , Nov. 9, 2015 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced the continued expansion of its Resolaris™ clinical program in rare